PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
From only 80 Jan Aushadhi Kendras in 2014, there are around 11,000 units operating across the country today
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
The institution will be spread over an area of more than 8 acres
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
Sharma joined the Morepen Lab in 2004
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Acquisition of exclusive commercialization rights for European markets
Subscribe To Our Newsletter & Stay Updated
